This company has been marked as potentially delisted and may not be actively trading. NYSE:CBM Cambrex (CBM) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Cambrex Stock (NYSE:CBM) Get Cambrex alerts:Sign Up Key Stats Today's Range$59.99▼$59.9950-Day Range$59.99▼$59.9952-Week Range$33.80▼$60.29VolumeN/AAverage Volume218,726 shsMarket Capitalization$2.02 billionP/E Ratio21.66Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey. Read More Receive CBM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cambrex and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CBM Stock News HeadlinesPermira seeks $4bn for sale of contract drugmaker CambrexSeptember 6, 2025 | ft.comPermira seeks $4 billion for sale of contract drugmaker Cambrex, FT reportsSeptember 6, 2025 | reuters.comArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves. | Banyan Hill Publishing (Ad)Cambrex Announces Strategic Agreement with Lilly to Support Biotech Collaborator ManufacturingDecember 5, 2024 | finance.yahoo.comSemi-Solid Dosage CDMO Market Report 2024-2030: The Lubrizol Corporation, Cambrex Corporation, and Contract Pharmaceuticals Dominate the Competitive LandscapeNovember 13, 2024 | globenewswire.comCambrex Opens New Stability Storage Facility in Durham, North CarolinaOctober 17, 2024 | finance.yahoo.comCambrex Announces New Liquid-Phase Peptide Synthesis Manufacturing TechnologySeptember 19, 2024 | finance.yahoo.comFire, gas leak at Cambrex manufacturing facility, Triad officials sayJuly 31, 2024 | msn.comSee More Headlines CBM Stock Analysis - Frequently Asked Questions How were Cambrex's earnings last quarter? Cambrex Co. (NYSE:CBM) released its earnings results on Thursday, August, 2nd. The biotechnology company reported $0.74 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.05. The firm's revenue for the quarter was up 13.0% compared to the same quarter last year. What other stocks do shareholders of Cambrex own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cambrex investors own include Bristol Myers Squibb (BMY), Illumina (ILMN), AbbVie (ABBV), Meta Platforms (META), CVS Health (CVS), Gilead Sciences (GILD) and NVIDIA (NVDA). Company Calendar Last Earnings8/02/2018Today10/11/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical Preparations Sub-IndustryLife Sciences Tools & Services Current SymbolNYSE:CBM CIK820081 Webwww.cambrex.com Phone201-804-3000FaxN/AEmployees1,732Year FoundedN/AProfitability EPS (Trailing Twelve Months)$2.77 Trailing P/E Ratio21.66 Forward P/E RatioN/A P/E GrowthN/ANet Income$92.41 million Net Margins5.96% Pretax MarginN/A Return on Equity5.38% Return on Assets2.50% Debt Debt-to-Equity Ratio0.76 Current Ratio2.37 Quick Ratio1.70 Sales & Book Value Annual Sales$532.09 million Price / Sales3.80 Cash Flow$3.91 per share Price / Cash Flow15.36 Book Value$19.48 per share Price / Book3.08Miscellaneous Outstanding Shares33,720,000Free FloatN/AMarket Cap$2.02 billion OptionableOptionable Beta2.14 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NYSE:CBM) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cambrex Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cambrex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
